Lawrence Annable, PhD
Primary Axis:
Mental Illness and Addiction
Email:
Email contact form Research Focus:
Epidemiological studies of risk factors for tardive dyskinesia and extrapyramidal symptoms in schizophrenic patients treated with antipsychotic medication. Statistical investigation of factors related to treatment response in psychiatric disorders. Design and statistical analysis of randomized controlled clinical trials of new treatments for psychiatric disorders.Tardive dyskinesia, extrapyramidal symptoms, clinical trials, epidemiology, psychopharmacology, schizophrenia, depression, anxiety disorders, research ethics
Keywords:
Tardive dyskinesia, extrapyramidal symptoms, clinical trials, epidemiology, psychopharmacology, schizophrenia, depression, anxiety disorders, research ethics
Location:
Research and Training Building Publications:
Klein MB, Cooper C, Brouillette M-J, Sheehan NL, Benkelfat C, Annable L, Weston F, Kraus D, Singer J; CTN194 investigators: CTN-194 (PICCO): Design of a trial of citalopram for the prevention of depression and its consequences in HIV-Hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Contemporary Clinical Trials 29:617-630; 2008.
Lal S, Thavundayil JX, Nair NPV, Annable L, Ng Ying Kin NMK, Gabriel A, Desjardins B, Schwartz G: Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. Journal of Psychiatry and Neuroscience 31:271-279; 2006
Myhr G, Talbot J, Annable L, Pinard G: Suitability for short-term cognitive behavioral therapy. Journal of Cognitive Psychotherapy 21:334-345; 2007
